SOLICITATION NOTICE
A -- Therapeutic for treatment of Thrombocytopenia arising from H-ARS
- Notice Date
- 6/15/2022 7:47:50 AM
- Notice Type
- Presolicitation
- Contracting Office
- BARDA - ASPR / DAAPPO / BARDA DCMA WASHINGTON DC 20515 USA
- ZIP Code
- 20515
- Solicitation Number
- 75A50122R00021
- Archive Date
- 07/15/2022
- Point of Contact
- Richard Hall
- E-Mail Address
-
Richard.Hall@hhs.gov
(Richard.Hall@hhs.gov)
- Description
- Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) intends to use Project BioShield (PBS) to procure a U.S. Food and Drug Administration (FDA) approved thrombopoietin receptor agonist, for use as a MCM that can treat thrombocytopenia arising as a pathology of acute exposure to ionizing radiation that may be a consequence of a radiological/nuclear mass casualty event . The procured therapeutic will be delivered to the ASPR/Strategic National Stockpile and maintained as vendor managed inventory. The USG seeks therapeutics that meet the following mandatory� criteria: 1) The approved label indication shall be to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation H-ARS and 2) The approved label shall state the drug�s mechanism of action is through stimulation of thrombopoiesis and/or treatment of thrombocytopenia resulting in a statistically significant increase in platelet counts and 3) The MCM is effective when administered at 24-hours or more post-radiation exposure.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/af73201d1a0a4757803cb3274f0b25a6/view)
- Record
- SN06358849-F 20220617/220615230106 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |